Dual Antiplatelet Therapy in Acute Ischemic Stroke

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Stroke recurrence is common in the early period after a cerebral ischemic event. Treatment with an antiplatelet agent is recommended to reduce recurrent stroke and death in patients with a non-cardioembolic ischemic stroke and transient ischemic attack. Compared to monotherapy, dual antiplatelet therapy has more robust inhibition of platelet activation but a higher risk of systemic bleeding and intracranial hemorrhage. Randomized controlled trials and meta-analyses suggest that short-term use of dual antiplatelet treatment initiated early after ischemic stroke and TIA reduces the risk of recurrent stroke and major vascular events without significantly increasing the hemorrhagic complication rates, particularly in those with large-vessel disease, while long-term dual antiplatelet treatment increases the risk of systemic and intracranial hemorrhage over time, offsetting any potential benefit. Until further data becomes available, clinicians should carefully assess this risk and benefit in each case and continually reevaluate the need for prolonged dual antiplatelet therapy.

Original languageEnglish (US)
Article number37
JournalCurrent Atherosclerosis Reports
Volume17
Issue number7
DOIs
StatePublished - Jul 26 2015

Fingerprint

Stroke
Intracranial Hemorrhages
Therapeutics
Platelet Aggregation Inhibitors
Transient Ischemic Attack
Platelet Activation
Blood Vessels
Meta-Analysis
Randomized Controlled Trials
Hemorrhage
Recurrence

Keywords

  • Antiplatelet therapy
  • Aspirin
  • Cerebral infarction
  • Clopidogrel
  • Ischemic stroke
  • Transient ischemic attack

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Dual Antiplatelet Therapy in Acute Ischemic Stroke. / Asdaghi, Negar; Romano, Jose G.

In: Current Atherosclerosis Reports, Vol. 17, No. 7, 37, 26.07.2015.

Research output: Contribution to journalArticle

@article{d3e28468c2d74e0c961b0255c68c4062,
title = "Dual Antiplatelet Therapy in Acute Ischemic Stroke",
abstract = "Stroke recurrence is common in the early period after a cerebral ischemic event. Treatment with an antiplatelet agent is recommended to reduce recurrent stroke and death in patients with a non-cardioembolic ischemic stroke and transient ischemic attack. Compared to monotherapy, dual antiplatelet therapy has more robust inhibition of platelet activation but a higher risk of systemic bleeding and intracranial hemorrhage. Randomized controlled trials and meta-analyses suggest that short-term use of dual antiplatelet treatment initiated early after ischemic stroke and TIA reduces the risk of recurrent stroke and major vascular events without significantly increasing the hemorrhagic complication rates, particularly in those with large-vessel disease, while long-term dual antiplatelet treatment increases the risk of systemic and intracranial hemorrhage over time, offsetting any potential benefit. Until further data becomes available, clinicians should carefully assess this risk and benefit in each case and continually reevaluate the need for prolonged dual antiplatelet therapy.",
keywords = "Antiplatelet therapy, Aspirin, Cerebral infarction, Clopidogrel, Ischemic stroke, Transient ischemic attack",
author = "Negar Asdaghi and Romano, {Jose G}",
year = "2015",
month = "7",
day = "26",
doi = "10.1007/s11883-015-0515-8",
language = "English (US)",
volume = "17",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "7",

}

TY - JOUR

T1 - Dual Antiplatelet Therapy in Acute Ischemic Stroke

AU - Asdaghi, Negar

AU - Romano, Jose G

PY - 2015/7/26

Y1 - 2015/7/26

N2 - Stroke recurrence is common in the early period after a cerebral ischemic event. Treatment with an antiplatelet agent is recommended to reduce recurrent stroke and death in patients with a non-cardioembolic ischemic stroke and transient ischemic attack. Compared to monotherapy, dual antiplatelet therapy has more robust inhibition of platelet activation but a higher risk of systemic bleeding and intracranial hemorrhage. Randomized controlled trials and meta-analyses suggest that short-term use of dual antiplatelet treatment initiated early after ischemic stroke and TIA reduces the risk of recurrent stroke and major vascular events without significantly increasing the hemorrhagic complication rates, particularly in those with large-vessel disease, while long-term dual antiplatelet treatment increases the risk of systemic and intracranial hemorrhage over time, offsetting any potential benefit. Until further data becomes available, clinicians should carefully assess this risk and benefit in each case and continually reevaluate the need for prolonged dual antiplatelet therapy.

AB - Stroke recurrence is common in the early period after a cerebral ischemic event. Treatment with an antiplatelet agent is recommended to reduce recurrent stroke and death in patients with a non-cardioembolic ischemic stroke and transient ischemic attack. Compared to monotherapy, dual antiplatelet therapy has more robust inhibition of platelet activation but a higher risk of systemic bleeding and intracranial hemorrhage. Randomized controlled trials and meta-analyses suggest that short-term use of dual antiplatelet treatment initiated early after ischemic stroke and TIA reduces the risk of recurrent stroke and major vascular events without significantly increasing the hemorrhagic complication rates, particularly in those with large-vessel disease, while long-term dual antiplatelet treatment increases the risk of systemic and intracranial hemorrhage over time, offsetting any potential benefit. Until further data becomes available, clinicians should carefully assess this risk and benefit in each case and continually reevaluate the need for prolonged dual antiplatelet therapy.

KW - Antiplatelet therapy

KW - Aspirin

KW - Cerebral infarction

KW - Clopidogrel

KW - Ischemic stroke

KW - Transient ischemic attack

UR - http://www.scopus.com/inward/record.url?scp=84930211118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930211118&partnerID=8YFLogxK

U2 - 10.1007/s11883-015-0515-8

DO - 10.1007/s11883-015-0515-8

M3 - Article

C2 - 25990661

AN - SCOPUS:84930211118

VL - 17

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 7

M1 - 37

ER -